1、INTERIM REPORT 2019 中期報告CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正 大 企 業 國 際 有 限 公 司Incorporated in Bermuda with limited liability Stock Code:3839於 百 慕 達 註 冊 成 立 之 有 限 公 司 股份代號:383901I N T ER I M R EP O R T 2019二 零 一 九 年 中 期 報 告正 大 企 業 國 際 有 限 公 司 CHIA TAI ENTERPRISES INTERNATIONAL LIMITED2Managem
2、ent Discussion and Analysis 管理層討論及分析6Report on Review of Interim Financial Report 中期財務報告之審閱報告8Consolidated Statement of Comprehensive Income 綜合全面收益表10Consolidated Statement of Financial Position 綜合財務狀況表12Consolidated Statement of Changes in Equity綜合權益變動表14Condensed Consolidated Statement of Cash Flo
3、ws 簡明綜合現金流量表15Notes to Interim Financial Report 中期財務報告附註33Other Information 其他資料39Corporate Information 公司資料 Contents目 錄02I N T ER I M R EP O R T 2019二 零 一 九 年 中 期 報 告正 大 企 業 國 際 有 限 公 司 CHIA TAI ENTERPRISES INTERNATIONAL LIMITEDGROUP RESULTSChia Tai Enterprises International Limited(the“Company”and
4、,together with its subsidiaries,the“Group”)has two lines of businesses:biochemical business and industrial business.The biochemical business,which focuses on the manufacture and sale of chlortetracycline(“CTC”)products and is carried on by Group subsidiaries,accounts for all of the Groups consolidat
5、ed revenue.The industrial business comprises the Groups interests in its joint venture ECI Metro Investment Co.,Ltd.(together with its subsidiaries,“ECI Metro”),and its associate Zhanjiang Deni Vehicle Parts Co.,Ltd.(together with its subsidiaries,“Zhanjiang Deni”).The results of the Groups industri
6、al business are incorporated in the consolidated statement of comprehensive income as share of profits from joint venture and associate.For the six months ended 30 June 2019(“1H19”),the Groups revenue was US$50.42 million,an increase of 18.5%compared to the first half of 2018(“1H18”).Gross profit ma